Julie R. Gralow, MD, clinical director, Breast Medical Oncology, Seattle Cancer Care Alliance, professor, medical oncology, University of Washington School of Medicine, discusses the global impact of biosimilars in HER2-positive breast cancer.
Experts discuss optimizing TKI selection and sequencing strategies for advanced gastrointestinal stromal tumors (GIST) beyond first-line therapy, focusing on the latest clinical data, molecular characterization,…
The EMA’s CHMP has issued a positive opinion regarding the use of subcutaneous daratumumab in high-risk smoldering myeloma.
Relacorilant plus nab-paclitaxel improved survival in platinum-resistant ovarian cancer with a primary platinum-free interval of 1 to 6 months.
The European Medicines Agency’s CHMP has recommended the approval of darolutamide plus ADT in mHSPC in the European Union.
The EMA’s CHMP has issued a positive opinion for UM171 cell therapy for patients with hematological malignancies and limited stem cell transplant options.
The EMA’s CHMP has recommended the approval of cabozantinib for patients with pancreatic and extra-pancreatic neuroendocrine tumors.
The EMA’s Committee for Medicinal Products for Human Use granted a positive opinion for nirogacestat for the treatment of patients with desmoid tumors.
CHMP recommended ibrutinib plus immunochemotherapy for previously untreated, transplant-eligible mantle cell lymphoma.
Bladder tumors that have been excluded from clinical trials have a few things in common that could lead to new therapies.
Emil Lou, MD, PhD, FACP, discusses the potential applicability of CRISPR-Cas9–mediated CISH knockout to bolster TIL responses in drug-refractory GI tumors.
